off label tirzepatide is a novel medication that the FDA has approved for treating type 2 diabetes mellitus. Due to its potent weight loss properties, Tirzepatide can be used off-label for treating obesity. • • # Off-label use of semaglutide and

Adachi Y, Kato T, Yamada T, Murata D, Arai K, Stahelin RV, et al

Keep a record of any side effects and report persistent or concerning symptoms promptly

New Trends in the Field Triple-agonist therapies approaching weight loss levels previously seen only with bariatric surgery Oral formulations that eliminate the need for injections, improving access and patient preference Monthly or less frequent dosing options to improve adherence Enhanced understanding of how combining different hormonal pathways can optimize weight loss and metabolic health Weight Loss Medications in the Pipeline Researchers are evaluating several promising agents in late-stage clinical trials: Retatrutide : A triple GIP/GLP-1/glucagon receptor agonist that demonstrated weight loss of approximately 24% at 48 weeks on the 12 mg dose

Small variations in raw material sourcing, extraction conditions or storage can lead to measurable differences in finished product composition

doi: 10.1186/s42269-019-0227-2 42 PasareCMedzhitovR

While LifeMD does provide physician access, patients may not receive the same level of targeted guidance or structured engagement when the focus is on metabolic health